Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Myocardial Reperfusion InjuryCardiac Output, Low
Interventions
DRUG

Perhexiline

Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.

DRUG

Placebo marked PEXSIG

Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.

Trial Locations (2)

B15 2TH

University Hospital Birmingham, Birmingham

BN2 5BE

Brighton & Sussex University Hospitals NHS Trust, Brighton

All Listed Sponsors
collaborator

University of Birmingham

OTHER

collaborator

Brighton and Sussex University Hospitals NHS Trust

OTHER

collaborator

British Heart Foundation

OTHER

lead

University Hospital Birmingham

OTHER

NCT00845364 - Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery | Biotech Hunter | Biotech Hunter